INNODIA DETECT Program in Collaboration with Enable Biosciences and Lund University
INNODIA's proud to announce a new collaboration with Enable Biosciences, a global leader in ultrasensitive antibody diagnostic technology, and the Celiac Disease and Diabetes Unit (CDDU) at Lund University’s Clinical Research Center (CRC) in Malmö, Sweden, for the of the DETECT Program. This key initiative aims to expand early detection of Type 1 Diabetes (T1D) across Europe. The DETECT Program will screen unaffected family members of individuals with T1D at participating INNODIA clinical sites. Through dried blood spot (DBS) samples and Enable’s ADAP DNA barcoding technology, the program will detect the presence of islet autoantibodies (IAb)—the earliest indicators of preclinical T1D.
A Key Milestone in Early Detection and Prevention
The goal of DETECT is to identify individuals at an early stage of T1D, providing opportunities to participate in preventive clinical trials and, in the near future, to access approved therapies aimed at halting disease progression. The first dedicated testing hub is now live at Lund University’s CRC in Malmö, one of Europe’s leading centers for autoimmune disease screening. Over the years, INNODIA plans to expand DETECT with additional testing hubs across Europe.
Manuela Battaglia, Managing Director of INNODIA, commented: “INNODIA is proud to support early T1D detection across Europe through our clinical site Members, accelerating the identification of individuals with early T1D to ensure they have access to all possible therapeutic options and to facilitate the development and implementation of preventive clinical trials.”
Empowering Families Through Accessible, Accurate Testing
By using Enable Biosciences’ ADAP technology, which has been validated and applied by Lund CRC for over five years, DETECT enables highly sensitive and specific detection of autoantibodies through minimally invasive DBS testing. This approach increases accessibility and comfort for participants and simplifies sample collection.
Dr. David Seftel, CEO of Enable Biosciences, added: “Enable Biosciences is honored to partner with the dynamic leadership of INNODIA in this significant step toward widespread early detection and prevention of Type 1 Diabetes. Our ADAP technology and tailored reagents will enable INNODIA’s network of testing hubs to expand access to effective and accurate early preclinical T1D detection.” This collaboration is made possible through the support of an unrestricted grant from Sanofi, that helps INNODIA bring innovative screening programs like DETECT to communities across Europe.
Supporting Families and Advancing Precision Medicine
The DETECT Program supports INNODIA’s broader mission to accelerate the development of curative therapies for T1D. INNODIA has also unveiled the INNODIA Early T1D Navigator Tool at ATTD 2025 (The INNODIA Early T1D Navigation Tool | INNODIA). This digital resource will help interested individuals find the closest clinical sites offering screening and monitoring services, ensuring that people who wants to be tested and those who test positive for IAb can be connected to the appropriate care and trials.
See joint Press release March 19, 2024 to find out more.
INNODIA works together with Diamyd Medical to enhance participant recruitment for the DIAGNODE-3 precision medicine trial
INNODIA is excited to announce its collaboration with Diamyd Medical!
Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development. It is focused on developing precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (Latent Autoimmune Diabetes in Adults).
Through this newly established collaboration with INNODIA, the aim is to increase patient recruitment for DIAGNODE-3, their current precision medicine trial in people with Stage 3 T1D. The study is actively recruiting patients in the US and 8 European countries, and the aim is to evaluate the safety and efficacy of the Diamyd antigen-specific immunotherapy in individuals with Type 1 Diabetes.
“We are delighted to work with INNODIA to spread the awareness of Type 1 Diabetes and Diamyd®, as well as to ensure that we meet critical recruitment milestones in DIAGNODE-3 ahead of a potential BLA under the Accelerated Approval Program”, says Ulf Hannelius, CEO of Diamyd Medical.
“By joining forces with Diamyd Medical, we are advancing our shared mission of improving lives for persons with Type 1 Diabetes”, says Manuela Battaglia, Managing Director of INNODIA. “INNODIA’s network will be instrumental in reaching patients across Europe, contributing to this transformative effort.”
See Diamyd Medical Press release, November 5, 2024 to find out more.